In This Issue

Accreditation Statistics

As of August 1, 2023

Cellular Therapy Entities

  • Accredited: 255
  • Applicants: 26

Cord Blood Banks

  • Accredited: 53
  • Applicants: 9

Congratulations to the following organizations for achieving initial accreditation:

Pennsylvania Hospital, Penn Medicine: Adult autologous hematopoietic progenitor cellular therapy, peripheral blood cellular therapy product collection, and cellular therapy product processing with minimal manipulation

Sarah Cannon Transplant & Cellular Therapy Program at MountainView Hospital: Adult autologous hematopoietic progenitor cellular therapy, immune effector cellular therapy administration, peripheral blood cellular therapy product collection, and cellular therapy product processing with minimal manipulation

A complete list of accredited organizations can be found at www.factglobal.org.

Study Finds Transplant Centers Accredited Under FACT-JACIE Standards Comply Significantly Better with Related Donor Care Standards

Posted in :: 2016 Volume I :: Thursday, April 14th, 2016

In an article published in Biology of Blood and Marrow Transplantation (BBMT), European Society for Blood and Marrow Transplantation (EBMT)-member transplant centers accredited under the FACT-JACIE Hematopoietic Cell Therapy Standards were found to comply significantly better with related donor care standards. Results described in European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards (Anthias, O’Donnell, et al, 2016,  doi: http://dx.doi.org/10.1016/j.bbmt.2015.11.009) show practice at these accredited centers was closer to recommended standards compared with non-accredited centers, including the use of eligibility criteria and avoiding conflicts of interest between transplant recipient and donor needs.

The study did find some areas of related donor care with room for improvement. Where standards do not exist, neither accredited and non-accredited centers met accepted best practice, illustrating that a risk of undue pressure on related donors and a risk of donation-associated adverse events is still present. The authors recommend measures to address these risks through enhanced regulatory standards and initiatives to standardize care of related donors.